65 related articles for article (PubMed ID: 11329782)
1. [Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy].
Tsushima T; Kobashi K; Akebi N; Yamato T; Asahi T; Maki Y; Ohmori H
Gan To Kagaku Ryoho; 2001 Apr; 28(4):483-91. PubMed ID: 11329782
[TBL] [Abstract][Full Text] [Related]
2. [Phase I study of amrubicin hydrochroride (SM-5887) for superficial bladder cancer in intravesical chemotherapy].
Ohmori H; Yamato T; Asahi T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):475-82. PubMed ID: 11329781
[TBL] [Abstract][Full Text] [Related]
3. [Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Kotake T; Koyanagi T; Akaza H; Shimazaki J; Ito H; Hosaka M; Okajima E; Saito Y; Miyanaga N; Kuroda M; Hirao Y
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1189-95. PubMed ID: 9679582
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
6. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
10. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Furue H; Machida T; Masaoka T; Ikeda S
Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
[TBL] [Abstract][Full Text] [Related]
11. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
14. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
15. [A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
Hashimura T; Shirahase T; Inoue T; Yamasaki T; Terada N; Ogura K; Arai Y; Hida S; Ueda T
Hinyokika Kiyo; 2005 Jul; 51(7):439-42. PubMed ID: 16119805
[TBL] [Abstract][Full Text] [Related]
16. [Intravesical chemotherapy with 4'-EPI-adriamycin in patients with superficial bladder tumors (randomized study)].
Tsushima T; Matsumura Y; Ozaki Y; Akagi T; Obama T; Nasu Y; Ohmori H
Hinyokika Kiyo; 1985 Dec; 31(12):2215-8. PubMed ID: 3868934
[TBL] [Abstract][Full Text] [Related]
17. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
[TBL] [Abstract][Full Text] [Related]
19. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
